Results 221 to 230 of about 3,602,513 (298)

An analysis of cost-saving in the German statutory health insurance system due to the introduction of epoetin alfa biosimilars in Germany. [PDF]

Front Public Health
Raitner I, Müller B, Vijayan A, Zimmermann L, Bramlage P, Ness NH, Müller M.   +6 more
europepmc   +1 more source

Policy and legal perspectives on the traditional Chinese medicine varietal protection system (TCMVPS): reform or abolition? [PDF]

Front Pharmacol
Wang Y, Sun K, Hua D.
europepmc   +1 more source

Evaluating the corporate social responsibility agenda for high-cost novel therapies: roles for government and civil society. [PDF]

Health Res Policy Syst
Wong A, Saeed G, Garner S, Kohler J.
europepmc   +1 more source

Tertiary Patents on Drugs Approved by the FDA.

JAMA Health Forum
Teng TW, Tu SS, Mooney H, Bendicksen L, Gabriele SME, Wouters OJ, Feldman WB.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)

Chemical Reviews, 2014
José Luis Aceña, Santos Fustero, Vadim A Soloshonok   +2 more
exaly   +2 more sources

Analysis of competition and dominance in the russian pharmaceutical market

Pharmacoeconomics: theory and practice, 2022
The article presents an analysis of development trends, as well as the dynamics of dominance and competition among drug manufacturers, distributors, and pharmacy chains in the Russian pharmaceutical market.
N. Markov, E. Yakimova
semanticscholar   +1 more source

Pharmaceutical marketing

2022
Dr. Mohini Kalra, Dr.
Ranajit Nath, Ratul Bhowmik
openaire   +2 more sources